Local News

• Forest Laboratories reports fiscal first quarter 2009 earnings per share of $0.79  Forest Laboratories announced that fully diluted earnings per share equaled $0.79 in the first quarter of fiscal 2009. Reported earnings per share include a one-time pre- tax charge of $44,100,000, or $0.08 per share net of tax.
  Forest Laboratories, Inc. July 22, 2008  
• Merck announces fourth quarter 2008 dividend  The Board of Directors of Merck & Co. declared a quarterly dividend of $0.38 per share on the Company's common stock for the fourth quarter of 2008.
  Merck & Co., Inc. July 22, 2008  
• Senate Appropriations Committee approves $2 billion for FDA  The Senate Appropriations Committee unanimously passed an appropriations markup measure Thursday, providing the FDA with a $2.04 billion fiscal 2009 budget. This amount is $324.6 million more than the agency initially received for fiscal 2008.
  FDAnews July 21, 2008  
• Wyeth Pearl River Facility earns OSHA VPP Star; 2,000th workplace recognized in U.S.  Wyeth announced that its manufacturing and research facility in Pearl River, N.Y., has earned the highest recognition for workplace safety and health from the U.S. Department of Labor's Occupational Safety and Health Administration (OSHA): the Voluntary Protection Programs (VPP) "star."
  Wyeth July 21, 2008  
• Boston Scientific announces results for second quarter ended June 30, 2008  Boston Scientific announced financial results for the second quarter ended June 30, 2008, as well as guidance for net sales and earnings per share (EPS) for the third quarter of 2008. For the second quarter, the company achieved net sales of $2.024 billion.
  Boston Scientific Corporation July 21, 2008  
• Rexahn adds to cancer patent portfolio  Rexahn Pharmaceuticals has won its third patent for a cancer treatment in nine months. The Rockville-based company said the Patent and Trademark Office has issued a patent for RX-0183 and related compounds, small molecules that inhibit the proteins that signal cancer cells to grow.
  Washington Business Journal July 21, 2008  Tucker Echols
• Teva to acquire Barr  Teva Pharmaceutical and Barr Pharmaceuticals announced today that they have signed a definitive agreement under which Teva will acquire Barr, the fourth largest generic drug company worldwide. Each share of Barr common stock will be converted into $39.90 in cash and 0.6272 Teva ADRs.
  Barr Pharmaceuticals, Inc. July 18, 2008  
• U.S. cancels test of experimental AIDS vaccine  Federal researchers dropped plans for a large-scale test of an experimental AIDS vaccine developed by the National Institutes of Health - the latest fallout from the failure last September of a similar candidate from drugmaker Merck that may have left some volunteers more vulnerable to HIV.
  San Francisco Chronicle July 18, 2008  Sabin Russell
• Merck to fund U.S. VIOXX(R) product liability resolution program  Merck & Co. said that it is satisfied that the thresholds necessary to trigger funding of the program to resolve state and federal VIOXX myocardial infarction (MI) and ischemic stroke (IS) claims in the United States will be met.
  Merck & Co., Inc. July 17, 2008  
• Genzyme and PTC Therapeutics announce collaboration on small molecule for genetic disease  Genzyme and PTC Therapeutics announced an exclusive global collaboration to develop and commercialize PTC124, PTC's novel oral therapy in late-stage development for the treatment of genetic disorders due to nonsense mutations.
  Genzyme Corporation July 17, 2008  

   (next 10 articles)